Cancer Res Treat.  2004 Jun;36(3):161-162.

Cyclooxygenase-2: A Potential Target in Human Cancer

• Won JH

Abstract

No abstract available.

MeSH Terms

Cyclooxygenase 2*
Humans*
Cyclooxygenase 2

Reference

1. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002; 94:252–266. PMID: 11854387.

2. Hawk ET, Viner JL, Dannenberg A, DuBois RN. COX-2 in cancer-a player that's defining the rules. J Natl Cancer Inst. 2002; 94:545–546. PMID: 11959883.

3. Leahy KM, Ornberg RL, Wang Y, Zweifel BS, Koki AT, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002; 62:625–631. PMID: 11830509.

4. Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst. 1986; 77:1309–1313. PMID: 3099048.

5. Gasparini G, Longo R, Sarmiento R, Morabito A. Inhibitors of cyclo-oxygenase 2: a new class of anticancer agents? Lancet Oncol. 2003; 4:605–615. PMID: 14554238.

6. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler BB, Subbaramaiah K. Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer. Lancet Oncol. 2001; 2:544–551. PMID: 11905709.

7. Diaz A, Chepenik KP, Korn JM, Reginato AM, Jimenez SA. Differential regulation of cyclooxygenases 1 and 2 by interleukin-1 beta, tumor necrosis factor alpha, and transforming growth factor-beta 1 in human lung fibroblasts. Exp Cell Res. 1998; 241:222–229. PMID: 9633531.

8. Araki Y, Okamura S, Hussain SP, Nagashima M, He P, shiseki M, Miura K, Harris CC. Regulation of cyclooxygenase-2 expression by the Wnt and Ras pathways. Cancer Res. 2003; 63:728–734. PMID: 12566320.

9. Sheng H, Shao J, Dixon DA, Williams CS, Prescott SM, Du Bois RN, Beauchamp RD. Transforming growth factor enhances Ha-RAS-induced expression of cyclooxygenase-2 in intestinal epithelial cells via stabilization of mRNA. J Biol Chem. 2000; 275:6628–6635. PMID: 10692471.

10. Kang HJ, Gong G, Jang SJ, Jung PJ, Park CK. Expression of cyclooxygenase-2 in human breast carcinoma: Relevance to tumor angiogenesis and expression of estrogen receptor. Cancer Res Treat. 2001; 33:286–295.

11. Koki AT, Masferrer JL. Celecoxib: a specific COX-2 inhibitor with anticancer properties. Cancer Control. 2002; 9:28–35. PMID: 11965228.

12. Haller DG. COX-2 inhibitors in oncology. Semin Oncol. 2003; 4(Suppl 12):2–8. PMID: 14508721.

13. Ahn JH, Kim SB, Ahn SH, Gong GY, Ahn MJ, Kang YK, Lee JS, Kim WK. Clinical value of cyclooxygenase-2 expression in human breast cancer. Cancer Res Treat. 2004; 36:192–198.

14. Denkert C, Winzer KJ, Hauptmann S. Prognostic impact of cyclooxygenase-2 in breast cancer. Clin Breast Cancer. 2004; 4:428–433. PMID: 15023244.

15. Howe LR, Dannenberg AJ. A role for cyclooxygenase-2 inhibitors in the prevention and treatment of cancer. Semin Oncol. 2002; 29(Suppl 11):111–119. PMID: 12138405.